Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Day One Biopharmaceutical Q4 GAAP EPS $(0.69) Misses $(0.36) Estimate, Sales $29.21M Beat $27.79M Estimate

Author: Benzinga Newsdesk | February 25, 2025 04:23pm
Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.36) by 91.67 percent. This is a 7.81 percent decrease over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $29.21 million which beat the analyst consensus estimate of $27.79 million by 5.10 percent.

Posted In: DAWN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist